Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation

NCT03402295 is registered in ClinicalTrials.gov with Grupo de Estudos Multicentricos em Onco-Hematologia as lead sponsor.

NCT NCT03402295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation
Lead sponsor
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase
Phase 3
Overall status
Completed
Start date
June 15, 2009
Completion date
October 15, 2017
Enrollment
311 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

effects of chemotherapy, multiple myeloma